In the following video, Motley Fool health-care analyst David Williamson takes investors through what to expect from Bristol-Myers Squibb's (BMY +2.70%) upcoming earnings report and the important things to watch from this company moving forward.
Foolish Preview: Bristol-Myers Squibb
What to expect from Bristol-Myers Squibb's earnings report.
By Dave Williamson – Jan 23, 2013 at 7:33PM EST
Read Next
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Stocks Mentioned
Bristol Myers Squibb
NYSE: BMY
$58.94
(+2.70%)+$1.55
Pfizer
NYSE: PFE
$27.29
(+1.21%)+$0.33
Gilead Sciences
NASDAQ: GILD
$138.15
(+0.03%)+$0.04
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.